933 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
MRK Merck & Company, Inc. $70.42 $187.28B N/A
Article Searches
Stock Market News For Oct 30, 2019 http://www.zacks.com/stock/news/592891/stock-market-news-for-oct-30-2019?cid=CS-ZC--market_news-592891 Oct 30, 2019 - Benchmarks closed in the negative territory on Tuesday due to Alphabet's weak earnings report and uncertainties in timely completion of U.S-China Phase one deal.
Merck & Co Inc (MRK) Q3 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2019/10/29/merck-co-inc-mrk-q3-2019-earnings-call-transcript.aspx?source=iedfolrf0000001 Oct 29, 2019 - MRK earnings call for the period ending September 30, 2019.
Merck & Co., Inc. (MRK) CEO Ken Frazier on Q3 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4299956-merck-and-co-inc-mrk-ceo-ken-frazier-q3-2019-results-earnings-call-transcript?source=feed_sector_healthcare Oct 29, 2019 -
Merck (MRK) Tops Q3 Earnings Estimates http://www.zacks.com/stock/news/590173/merck-mrk-tops-q3-earnings-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_4-590173 Oct 29, 2019 - Merck (MRK) delivered earnings and revenue surprises of 20.80% and -99.89%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Strong Q3 Earnings Data Deluge http://www.zacks.com/stock/news/590714/strong-q3-earnings-data-deluge?cid=CS-ZC--economic_highlights-590714 Oct 29, 2019 - Strong Q3 Earnings Data Deluge
Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More http://www.zacks.com/stock/news/588895/drug-biotech-stock-q3-earnings-due-on-oct-29-mrk-pfe-more?cid=CS-ZC-FT-analyst_blog:_earnings_preview_-_esp|earnings_preview_-_esp-588895 Oct 28, 2019 - Four drug/biotech stocks are scheduled to release third-quarter results on Oct 29. Let's see how these companies are placed before their earnings call.
Why Earnings Season Could Be Great for Merck (MRK) http://www.zacks.com/stock/news/588664/why-earnings-season-could-be-great-for-merck-mrk?cid=CS-ZC-FT-tale_of_the_tape|earnings_surprise-588664 Oct 28, 2019 - Merck (MRK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Factors Setting the Tone for Bristol-Myers (BMY) Q3 Earnings http://www.zacks.com/stock/news/588782/factors-setting-the-tone-for-bristol-myers-bmy-q3-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-588782 Oct 28, 2019 - Investors will focus on regular top and bottom-line numbers along with updates on the Celgene merger, when Bristol-Myers (BMY) reports third-quarter results.
Can Merck (MRK) Keep the Earnings Beat Streak Alive in Q3? http://www.zacks.com/stock/news/582015/can-merck-mrk-keep-the-earnings-beat-streak-alive-in-q3?cid=CS-ZC-FT-analyst_blog|earnings_preview-582015 Oct 24, 2019 - Merck's (MRK) relatively newer products like Keytruda, Gardasil and Bridion are likely to have driven third-quarter sales. However, genericization of key drugs and increased competition are concerns.
3 Cancer Treatment Stocks to Buy Right Now https://www.fool.com/investing/2019/10/23/3-cancer-treatment-stocks-to-buy-right-now.aspx?source=iedfolrf0000001 Oct 23, 2019 - These stocks have track records of success and plenty of growth ahead.

Pages: 1234567...94

<Page 2>